A HIGH EFFICIENCY MAGNETIC BEARING ROTARY BLOOD PUMP

连续流动、旋转式动态血泵具有重要的医学价值。已经取得了一些成功，但这些设计中的大多数都是物理上很大的、电磁复杂的，并且消耗大量的功率。提出了一种新颖的单主动轴磁轴承血泵样机。主要设计特点包括被动径向轴承和拉拉轴向推力轴承。将设计一个非线性的轴向控制器，以实现一个“几乎为零功率”的系统，而不包括偏置磁铁。轴向轴承可以与叶轮叶片中的铁磁材料协同工作，从而消除了对叶轮护罩的需要。将使用速度而不是位移来控制转子位置，以进一步增强几乎为零功率的轴承运行。在液压方面，该设计结合了简单、有效的叶轮，以及允许良好洗涤流动的大型、低剪切通道。在第一阶段，将设计、建造和测试磁轴承系统，并使用采用立体光刻技术制造的泵进行测试。一种特殊的无铁心电机将最大限度地减少电机感应的磁性负载。电子控制器将不堪重负。该系统将在血液模拟溶液中进行全方位的性能测试。在第二阶段，将设计、建造可植入的原型，并进行广泛的工作台和体内测试，为第三阶段的资格鉴定做准备。拟议的商业应用：心脏病仍然是美国境内导致死亡和残疾的主要原因。在每年死于心脏相关问题的20万美国人中，大约有3万到6万人可能会通过心脏移植获救。然而，供体心脏的短缺阻碍了这一点，并刺激了许多机械心脏辅助和替代装置的发展。如果证明机械辅助泵足够安全可靠，改善心脏受损患者生活质量的潜在用途将极大地扩大市场。

Continuous flow, rotary dynamic blood pumps are of significant medical interest. Some successes have been achieved, but the majority of these designs are physically large, electromagnetically complex, and consume significant amounts of power. An innovative prototype blood pump incorporating a single active axis magnetic bearing is proposed. key design features include a passive radial bearing, and a pull-pull axial thrust bearing. A nonlinear axial controller will be designed, to implement a "virtually zero power" system, without incorporating bias magnets. The axial bearing can function in cooperation with ferromagnetic material in the impeller blades, eliminating the need for an impeller shroud. Velocity, rather than displacement, control of the rotor position will be used, to further enhance a virtually zero power bearing operation. Hydraulically, the design incorporates simple, effective impellers, and large, low-shear passages that allow good wash flow. In Phase I, a magnetic bearing system will be designed, built, and tested with a pump fabricated using stereolithography technology. A special, ironless motor will minimize motor-induced magnetic loads. The electronic controller will be breadboarded. This system will be performance tested in blood analog solution, in all orientations. During Phase II, an implantable prototype will be designed, built, and extensively bench and in-vivo tested, preparatory to Phase III qualification. PROPOSED COMMERCIAL APPLICATIONS: Heart disease remains the leading cause of death and disability within the United States. Of the 200,000 Americans who die each year due to heart- related problems, about 30,000 to 60,000 could probably be saved with heart transplants. However, the shortage of donor hearts precludes this, and has stimulated the development of many mechanical heart assist and replacement devices. Should mechanical assist pumps prove sufficiently safe and reliable, the potential use to improve the quality of life for cardiac-impaired patients dramatically expands the market.